Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

RNA

GreenLight to go public via $1.2 billion SPAC deal

by Michael McCoy
August 19, 2021 | A version of this story appeared in Volume 99, Issue 30

 

GreenLight Biosciences will go public by merging with a special purpose acquisition company (SPAC) in a deal that values GreenLight at about $1.2 billion. The Massachusetts-based firm was formed in 2008 to develop a cell-free method of making RNA. It is pursuing both agriculture and human therapeutic markets. GreenLight says one of its first products will be an RNA-based pesticide that protects potatoes from the Colorado potato beetle.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.